Dr Charles Rudin speaks to ecancer about the results from the KEYNOTE-604 study, which he presented at the ASCO 2020 virtual meeting.
Dr Rudin describes the design of this phase III study, which investigated the addition of pembrolizumab or placebo to etoposide and platinum regimens as first-line therapy for extensive-stage small-cell lung cancer (SCLC).
He states that the addition of pembrolizumab to platinum and etoposide significantly improved progression-free survival compared to placebo. Overall survival also appeared to favour the combination of pembrolizumab, platinum and etoposide also, but did not meet the significance threshold.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.